Evotec SE (EVO) Cash from Investing Activities Growth (1y) (2010 - 2026)
Evotec SE (EVO) Cash from Investing Activities Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evotec SE | 692.56 Mn | 692.08 Mn | - | 35.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.95% |
| Dec 31, 2025 | 362.98% |
| Sep 30, 2025 | 70.26% |
| Jun 30, 2025 | 26.27% |
| Mar 31, 2025 | 32.31% |
| Dec 31, 2024 | -430.62% |
| Sep 30, 2024 | -116.42% |
| Jun 30, 2024 | -228.16% |
| Mar 31, 2024 | -772.15% |
| Dec 31, 2023 | 96.60% |
| Sep 30, 2023 | 94.28% |
| Jun 30, 2023 | 122.17% |
| Mar 31, 2023 | 104.65% |
| Dec 31, 2022 | -51.38% |
| Sep 30, 2022 | -487.98% |
| Jun 30, 2022 | -202.03% |
| Mar 31, 2022 | -191,439.37% |
| Jun 30, 2010 | 20.31% |
| Mar 31, 2010 | -256.04% |